Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
Find out how Cartesian Therapeutics’ WestGene deal could reshape in vivo CAR-T strategy in autoimmune disease and what risks remain.
Pharma & Biotech
Pharma & Biotech
Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
Find out how TG Therapeutics’ BRIUMVI data could shape a new maintenance strategy in myasthenia gravis treatment.
Pharma & Biotech
Oral complement therapy for myasthenia gravis? Novartis’ iptacopan enters the neurology arena
Novartis gains FDA orphan status for iptacopan in myasthenia gravis. Explore how this oral complement inhibitor could challenge biologics in neurology.